Literature DB >> 12601227

A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants.

C Faravelli1, F Cosci, M Ciampelli, M A Scarpato, R Spiti, V Ricca.   

Abstract

OBJECTIVE: To compare the effectiveness of serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) for anxiety and mood disorders in a naturalistic setting.
METHODS: 114 of 2,000 outpatients drawn from a private facility with a diagnosis of mood or anxiety disorder had two separate episodes during which they were treated once with a SSRI and once with a TCA. The drugs had to be in monotherapy and appropriate according to the recent guidelines. Key outcome measures included several rating scales, the results of which were combined into three measures of outcome: full response (no symptom), partial response (residual symptoms), poor response.
RESULTS: TCAs produced a better response in 63 cases and SSRIs in 18 cases (p < 0.00001). When the outcome was dichotomized, TCAs were still superior (stricter criterion of full response: p = 0.0002; lower threshold: p < 0.0001). Considering depressive and anxiety disorders separately, TCAs remained superior in terms of efficacy (for depression: p < 0.0001; for anxiety: p = 0.026). Moreover, the second episode of illness showed a better outcome than the first (p = 0.0008).
CONCLUSIONS: In those cases where two different antidepressants were prescribed over two different episodes of illness, TCAs were significantly more effective than SSRIs, regardless of the type of disorder and order of prescription. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601227     DOI: 10.1159/000068689

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  4 in total

1.  Publication bias in complementary and conventional medicine.

Authors:  Alfredo Vannacci; Claudia Ravaldi; Fiammetta Cosci
Journal:  Eur J Clin Pharmacol       Date:  2005-03-11       Impact factor: 2.953

2.  The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials.

Authors:  J Craig Nelson; Yili Lu Pritchett; Oleg Martynov; Jimmy Y Yu; Craig H Mallinckrodt; Michael J Detke
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 3.  Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.

Authors:  Giovanni A Fava; Chiara Ruini; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells.

Authors:  Christiaan B Brink; Susanna L Viljoen; Susanna E de Kock; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2004-06       Impact factor: 3.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.